[Non-dopaminergic treatments for Parkinson's disease].
It has become increasingly evident over the past years that the pathological process in Parkinson's disease extends well beyond the substantia nigra and involves non-dopaminergic neurotransmitter systems that mediate motor and non-motor symptoms. In this article, both the pathophysiology and the pharmacological management of these non-dopaminergic symptoms are discussed.
Derkinderen
P
P
Inserm, U913, 44093 Nantes, France. derkinderenp@yahoo.fr
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D004298:Dopamine